Predictive Oncology Strengthens Offerings with GMP Lab and Addition of Leading Expert in Formulation Development
September 19 2022 - 8:30AM
Predictive Oncology (NASDAQ: POAI) today announced several key
developments to further strengthen the company’s offerings for
pharmaceutical and biotech customers.
First is Predictive Oncology’s Good Manufacturing Practices
(GMP) lab, which opens the opportunity to help clients move from
pre-clinical drug development to the investigational new drug (IND)
qualification, including phase 1 clinical trials. The company has
begun accepting orders.
“Adding GMP production capabilities at Predictive Oncology is a
major accomplishment that has been underway for the past year and a
half. This highly regulated designation, required by the FDA in the
manufacturing of pharmaceuticals, will generate opportunities for
added business growth for us and provide a valuable resource to our
customers. Keeping the development and production of our
proprietary endotoxin removal process in-house saves our customers
time and money, which is especially important at a time when drug
development companies face increased pressure to get to clinical
trials faster,” noted J. Melville Engle, CEO of Predictive
Oncology.
Second, Predictive Oncology is pleased to announce the addition
of a strategic advisor with two decades of experience in drug
development. As a consultant to the company, Dr. Kamal Egodage,
President of Canopy Biopharma, will lead formulation development
and sales growth strategies for Predictive Oncology’s drug
formulation area of business. Dr. Egodage will oversee the
development and sales of formulations that solubilize and stabilize
biological therapeutics, including vaccines that encompass
proteins, peptides, virus-like particles and whole live attenuated
viruses.
A proven leader in the biopharmaceutical industry, Dr. Egodage
brings over 25 years of experience in pharmaceutical, biotechnology
and biotech start-up environments in the US, Europe and Asia. He
has supported over 75 pharmaceutical products through analytical
and formulation development, clinical trials, commercialization and
post-marketing lifecycle management.
“Dr. Egodage brings an in-depth knowledge of the
biopharmaceutical regulatory and development process that makes him
an ideal fit for the growth plans we have at Predictive Oncology.
He has the vision, passion and understanding to help expand our
business growth in the area of formulation solutions,” explained
Larry DeLucas, PhD., Senior Vice President of Operations at
Predictive Oncology.
Dr. Egodage’s engagement comes at a time of growth for
Predictive Oncology with the GMP lab and launch of two new
products.
- Today, Predictive Oncology announces the next generation of a
classical static light scattering (SLS) instrument that will be the
first of its kind. The Free Flow SLS instrument is a rapid
automated static light scattering system that will expand the
company’s offerings with additional throughput capabilities in
developing formulations for customers with proteins, peptides,
vaccines and whole attenuated virus vaccines.
- The company also is introducing a new high-capacity endotoxin
column, called EndoBind-R II, which more effectively removes
endotoxins from aqueous samples. This is a non-epoxy media with a
high concentration of peptide bound that can be operated under HPLC
(high-pressure) conditions to reduce endotoxin levels below
required FDA levels.
Inquiries for the new products or GMP lab capabilities can be
made by emailing Larry DeLucas at LDelucas@solublebiotech.com.
About Predictive OncologyPredictive Oncology
(NASDAQ: POAI) is a knowledge-driven company focused on applying
artificial intelligence (AI) to develop optimal cancer therapies,
which can lead to more effective treatments and improved patient
outcomes. Through AI, Predictive Oncology uses a biobank of
150,000+ cancer tumors, categorized by patient type, against drug
compounds to help the drug discovery process and increase the
probability of success. The company offers a suite of
solutions for oncology drug development from early discovery to
clinical trials.
About Canopy BiopharmaCanopy Biopharma LLC is a
technical and business consultancy that supports biotherapeutics
development, regulatory strategies, and health authority
submissions from discovery to commercialization. Canopy Biopharma
enables a diverse small to medium sized biotech companies worldwide
to accelerate the development of therapeutics.
Public Relations Contact:Predictive
OncologyTheresa
Ferguson630-566-2003tferguson@predictive-oncology.com
Investor Relations Contact:Landon Capital Keith
Pinder(404) 995-6671kpinder@landoncapital.net
Forward-Looking Statements:Certain matters
discussed in this release contain forward-looking statements. These
forward-looking statements reflect our current expectations and
projections about future events and are subject to substantial
risks, uncertainties and assumptions about our operations and the
investments we make. All statements, other than statements of
historical facts, included in this press release regarding our
strategy, future operations, future financial position, future
revenue and financial performance, projected costs, prospects for
new and existing products and in general, changes in management,
plans and objectives of management are forward-looking statements.
The words “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “would,” “target” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Our
actual future performance may materially differ from that
contemplated by the forward-looking statements as a result of a
variety of factors including, among other things, factors discussed
under the heading “Risk Factors” in our filings with the SEC.
Except as expressly required by law, the Company disclaims any
intent or obligation to update these forward-looking
statements.
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024